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Venous thromboembolism is a complex disease resulting from the interactions of several risk factors from diverse origins:
genetic, environmental and behavioral. Numerous studies have evidenced an association between genetic thrombophilia de-
fects and venous thromboembolism. However, the clinical relevance of genetic thrombophilia to recurrent venous thrombo-
embolism is not clear and the risks of long-term anticoagulant treatment usually outweigh any benefits of hereditary
thrombophilia screening. Therefore, in everyday clinical practice (outside of research protocols) hereditary thrombophilia
screening should be performed only in cases where such testing is likely to influence patient management.
 2007 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Venous thromboembolism (VTE) is a major source
of morbidity and mortality affecting an estimated
1/1000 people annually, with prevalence increasing
with age (in young individuals incidence of VTE is
1/100,000 people; by middle age it is approximately
1/1,000 and thereafter it increases steeply approach-
ing 1%/year in older age).1 VTE is a complex multi-
factorial disease where genetic, environmental and
other risk factors participate in determining an indi-
vidual predisposition to thrombotic events. Within
the last 15 years several genetic risk factors have
been described and investigated. This has led to diag-
nostic techniques, mostly molecular, becoming used
more widely. However, despite the overwhelming ob-
servational evidence of the association between he-
reditary thrombophilia and VTE, the implications of
thrombophilia screening for everyday clinical practice
remain uncertain. The most common inherited throm-
bophilias (FV Leiden mutation, prothrombin G20210A
mutation; deficits in protein C, S and antithrombin III)
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thrombotic events by influencing several factors par-
ticipating in the coagulation cascade (Table 1).
Why Performing an Inherited Thrombophilia
Screening ?
In this review we focus on some common situations
for which thrombophilia testing is usually requested
but where such testing may not actually be useful
for the management of patients. There are several rea-
sons why in every day practice doctors request a ge-
netic thrombophilia screen for their patients: (1) To
provide an explanation for VTE, (2) To assess risk of
VTE recurrence and therefore offer guidance in deter-
mining duration of anticoagulation, (3) To predict risk
in asymptomatic relatives.
1. To provide an explanation for VTE
In clinical practice one of the most frequently advo-
cated reasons for thrombophilia testing is to provide
an explanation for the venous thromboembolic event.
However, VTE is a complex multifactorial disease re-
sulting from the interaction of genetic, environmental,
and behavioral risk factors. Usually for VTE toar Surgery. Published by Elsevier Ltd. All rights reserved.
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need to occur simultaneously. Additionally, complex-
ity of VTE etiology is exacerbated by the dynamic in-
fluence of age. In fact, for a patient with a FV Leiden
mutation, the risk of developing a VTE will vary with
age. Absolute risk at early age is relatively low, even
in the presence of several predisposing factors. As
an example, risk is 1/10,000/year at 25e30 years of
age, it increases with the use of oral contraceptives
(3e4/10,000/year) and is further increased if concom-
itant FV Leiden mutation is present, but remains at an
absolute level of only 3/1,000/year. Since aging is
a risk factor for venous thrombosis by itself2,3 at a later
age fewer risk factors will be needed to develop sim-
ilar levels of absolute risk of VTE. Based on these ob-
servations and the complexity of VTE etiology, the
relative contribution of hereditary thrombophilia
when generalized to a whole patient population is
questionable. Epidemiological studies have shown
that only 50% of patients with VTE have a positive ge-
netic thrombophilia screen, but this percentage varies
when selected patient populations are screened.
Evaluation of a link between a potential risk factor
and VTE occurrence is not always easy although
a number of risk factors are known, new risk factors
are being described continually. However, some large
published trials have added to the knowledge of VTE
occurrence and single hereditary thrombophilias: i)
LETS is a European case-control study of unselected
patients aged <70 years without cancer who experi-
enced a first deep vein thrombosis (DVT),4 and ii)
LITE is an USA prospective cohort study of 21,680 in-
dividuals aged >65 years in which baseline risk
factors were assessed in relation to future VTE.5,6
Results from these two studies are similar (Fig. 1).
From these trials we gather the information that for
patients with the two most common hereditary
thrombophilias (FV Leiden mutation and prothrom-
bin G20210A mutation) the relative risk of VTE, in ab-
sence of concomitant risk factors, increases 3.7e7.9
fold for the heterozygous FV Leiden mutation and
1.9e2.8-fold for the prothrombin mutation
(G20210A). These increases are modest, given the
Table 1. Most frequent hereditary thrombophilia defects
Pro-thrombotic mechanism
Loss of
function
Deficiency in
antithrombin-III,
protein C, protein S
Deficiency of natural
occurring anticoagulants
Gain of
function
FV Leiden mutation FV Leiden is relatively
resistant to inactivation
by activated protein C
Prothrombin
(G20210A) mutation
Leads to increased levels of
prothrombin
Eur J Vasc Endovasc Surg Vol 34, October 2007high prevalence of these defects in the general popu-
lation and the true incidence of VTE. Such observa-
tions suggest that the mere presence of one or more
hereditary thrombophilic factors is not a sufficient ex-
planation for VTE development per se. This may be
explained partially by the fact that clinical penetrance
of hereditary thrombophilias is highly variable even
within a single family. Therefore, phenotypic expres-
sion is variable and, as already mentioned, depends
not only on the presence of one or multiple genetic
defects but also on the interaction with other concom-
itant risk factors.
2. To assess risk of VTE recurrence and determine
duration of anticoagulation
Another common reason for thrombophilia testing is
to assess risk of VTE recurrence thus offering guid-
ance to determine duration of anticoagulation.
Indeed, the main goal of anticoagulant treatment after
VTE is to prevent recurrence, and if the risk of recur-
rence is considered high then long term anticoagula-
tion may be offered to the patient. Does the presence
of genetic thrombophilia increase significantly this
risk of recurrence in a patient experiencing VTE?
The answer to this question is not straightforward.
In fact, data presented in the literature are often con-
tradictory and studies conducted so far are mainly
retrospective. Moreover, some of the genetic defects
(i.e. protein C, protein S, and antithrombin-III deficits)
are rare and therefore it is difficult to determine accu-
rately their impact on VTE recurrence. However,
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Fig. 1. Estimated relative risk of first time VTE in patients
with hereditary thrombophilia.4e6
485Hereditary Thrombophilia and VTEdespite all these limitations, some studies have pro-
vided insight as to the risk of VTE recurrence in the
presence of hereditary thrombophilia. In the LETS
study 474 unselected patients experiencing a first ep-
isode of VTE were followed for many years.7 The cu-
mulative recurrence rate in these patients was 16.5%
at 7 years. Recurrence rate for each genetic thrombo-
philia was low, after adjustment for sex, age, and anti-
coagulation, with mean estimated relative risks
always < 2 (Fig. 2). This also was true for combined
thrombophilic defects. Overall risk of recurrence
was not significantly increased in patients with hered-
itary thrombophilias compared with patients without
known such abnormalities. Similar results were ob-
tained in the CVTE study (Cambridge Venous Throm-
boembolism Study) where 570 patients of all ages
with a first episode of VTE, no cancer, and no anti-
phospholipids syndrome, were followed for 2 years
after stopping anticoagulant treatment.8 Interestingly,
in the CVTE study, patients with post surgical VTE
had a very low risk of VTE recurrence, and patients
with non-surgical risk factors had a significantly
lower risk of recurrence (8%) than patients with an id-
iopathic VTE (20%). In both groups of patients, idio-
pathic VTE and non-surgical risk factor VTE, no
significant difference in recurrence rates was observed
between patients with and without genetic evidence
of thrombophilia. Homozygous thrombophilic muta-
tions also can be present. Such homozygous muta-
tions have been hypothesized to increase further the
risk of VTE recurrence. However, data from the
LETS Cohort (n = 474; 7 yrs follow up)
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Fig. 2. Estimated relative risk of VTE recurrence in patients
with hereditary thrombophilia.7literature have suggested that this may not always
be relevant. The Procare group recently reported a rel-
ative risk of VTE recurrence of only 1.8 in those
patients homozygous for the FV Leiden mutation
compared to those heterozygous for the mutation.9
These observations strongly suggest that in unse-
lected patients with a first episode of VTE hereditary
thrombophilia screening does not help to predict VTE
recurrence and therefore should not be used to guide
decisions on duration of anticoagulant treatment. On
the contrary, clinical risk factors seem to play a major
role in risk prediction.
When deciding about long-term anticoagulation
benefits and risks have to be balanced, the principal
risk being an hemorrhagic event. This risk should be
substantially lower than the risk of VTE recurrence.
A recent trial, the European Prospective Cohort on
Thrombophilia (EPCOT), followed, for about 6 years,
patients with hereditary thrombophilia who experi-
enced a first VTE.10 Among these patients 44 of 180
patients not on long-term anticoagulation experienced
a recurrent VTE (5%/year) compared to 7 of 124 pa-
tients on long-term anticoagulation (1.1%/year). In
this latter group, the benefit of long-term anticoagula-
tion was offset by an 0.8%/year risk of major
hemorrhage.
Often for those patients who already have experi-
enced one or more VTE, genetic thrombophilia
screening is proposed in order to assess the need
for prophylaxis in future high-risk thrombotic situa-
tions. A large amount of data appearing in the liter-
ature over the last 15 years has clearly shown that
there is a need for antithrombotic prophylaxis in
future high risk situations for all patients who expe-
rienced VTE, especially if idiopathic, even without
the knowledge of the presence of a hereditary
thrombophilia.11
3. To predict risk in asymptomatic relatives
Screening of asymptomatic family members of patients
with hereditary thrombophilia who experienced VTE
is a controversial topic. In a large recent prospective
study, the European Prospective Cohort on Thrombo-
philia (EPCOT), 575 asymptomatic carriers of genetic
thrombophilia were followed for about 6 years.12 Inci-
dence of first VTE was higher in individuals with
thrombophilia than in controls (0.8% year vs. 0.1%
year) with a relative risk of 9 after adjustment for age
and sex. Annual incidence of first VTE was highest
for individuals with antithrombin-III deficit (1.7%
year) or with combined thrombophilic defects (1.6%
year) and lowest in individuals carrying the FV Leiden
Eur J Vasc Endovasc Surg Vol 34, October 2007
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occurred at an earlier age in thrombophilic individuals
than in controls. Mean age of onset was 40 years for
those with protein C, protein S, antithrombin-III defi-
ciencies or combined defects as compared to 63 years
of those individuals carrying the FV Leiden mutation
and control subjects. This interesting study shows
that the risk of first VTE is increased in carriers of
genetic thrombophilia, but that this risk remains still
low and does not outweigh the risk of major hemor-
rhage associated with prolonged anticoagulation
[(1e3% year], providing that the INR remains within
the therapeutic range of 2e3.10,13,14 These observations
suggest that long-term prophylactic anticoagulation is
not warranted for asymptomatic carriers of genetic
thrombophilias. Consequently, unselected genetic test-
ing of individuals with a positive familial history is
not fully justifiable. Additionally, one has to be aware
of the consequences that genetic screening results
may have on patients: anxiety in asymptomatic carriers
and false reassurance in negative ones.15 A reason for
genetic testing in individuals with a family history of
VTE is to offer appropriate prophylaxis in high-risk sit-
uations. However, one has to remember that: i) general
recommendations on VTE prophylaxis already include
antithrombotic treatment for all those patients experi-
encing high risk thrombotic situations, regardless of
the presence or absence of detectable genetic thrombo-
philia,11 and ii) these recommendations are even more
stringent for those patients with a positive family his-
tory of VTE.11
When is Hereditary Thrombophilia
Testing Useful?
In the preceding section of the review we have dis-
cussed situations where hereditary thrombophilia
screening is not appropriate. On the other hand, there
are clinical situations where such tests may be useful
and their indication should be discussed. Hereditary
thrombophilia testing may be appropriate in young
women desiring to use oral contraceptives (OCP)
and who have a family history of VTE, particularly
if idiopathic. Oral contraceptives may be considered
if screening is negative. On the contrary, careful coun-
selling should be provided if screening is positive.
Such patients should be aware of the increased throm-
botic risk, alternative contraception methods may be
proposed or the use of a less thrombogenic OCP. An-
other situation in which thrombophilia testing may be
useful for patient management is the case of a woman
desiring a first pregnancy who experienced a proximal
DVT following a lower limb fracture treated with
Eur J Vasc Endovasc Surg Vol 34, October 2007immobilization with a cast while on OCP 5 years pre-
viously. In this case, VTE risk factors were the use of
OCP (although she had been using it safely for 5
years) and concomitant transient risk factors (immobi-
lization and traumatism) that are no longer present. If
thrombophilia screening is positive the patient doctor
may want to discuss antithrombotic prophylaxis
throughout pregnancy and during the 6 weeks post
partum. On the contrary, if screening is negative
only post partum anticoagulation may be considered.
In a 60 year old man (with two daughters) developing
an idiopathic proximal DVT genetic thrombophilia
testing is unnecessary for the patient, since results
would not change therapeutic approach or future pro-
phylaxis. However, thrombophilia screening may be
performed and if this is positive, testing of the daugh-
ters may be appropriate to evaluate the need for anti-
thrombotic prophylaxis during a future pregnancy or
offer counselling in case of OCP use. In this latter case,
the cost of such tests should be discussed since in
some countries testing for prevention may not be cov-
ered by health insurance.
Main Pitfalls In Hereditary Thrombophilia Testing
During the last 20 years the number of laboratory tests
for the detection of hereditary thrombophilia has been
constantly increasing. In this article we briefly pointed
out situations for which genetic testing is not clinically
relevant for the future management of patients. Once
doctors decide to perform a thrombophilia screening
this should be done in the most appropriate condi-
tions to avoid misinterpretation of results, which
Negative 48%
Positive 30%
False positive 22%
Fig. 3. «Real world» laboratory testing results for patients
presenting with VTE. False positive results include deficits
in protein C and S and accounted for about 1/5 of all tests.
Adapted from ref 16.
487Hereditary Thrombophilia and VTEcould bring more harm than benefit to the patient. An
interesting paper published in 2006 evaluated the use
of thrombophilia screening in a large urban academic
tertiary care center.16 The results show the excessively
high number of false positive tests (Fig. 3). This was
mainly due to either inappropriate timing of testing
(acute phase of VTE) or testing while the patient
was on oral anticoagulants or pregnant.
In Table 2 the main pitfalls of hereditary
thrombophilia screening are indicated, emphasising
when to avoid testing to limit false positive results.
Another aspect to consider when interpreting results
is the wide normal ranges for protein C, S and
antithrombin-III. How should a slightly diminished
protein level be interpreted? In some situations
repeated testing may be necessary to confirm a
true deficiency.
Conclusion
Hereditary thrombophilia testing is commonly per-
formed in routine clinical practice for patients with
VTE or asymptomatic individuals from families with
a history of VTE. A number of studies have shown as-
sociations between genetic thrombophilic defects and
VTE however, the clinical relevance of this association
remains to be fully demonstrated. Recent data from
the literature show rather convincingly that in general
Table 2. Most common pitfalls in hereditary thrombophilia
testing
Laboratory test When to avoid testing Type of test
FV Leiden
mutation
Avoid performing the
activated protein C
resistance test during
pregnancy, and in presence
of anti-phospholipid
antibodies.
- Genotyping (PCR)
- Activated protein
C resistance
(aPTT-based assay,
indirect evidence)
Prothrombin
G20210A
mutation
- Genotyping (PCR)
Deficit in
protein C
Acute phase, ongoing
vitamin K antagonist
treatment, liver
dysfunction
- Protein C activity
- Antigenic assays*
Deficit in
protein S
Acute phase, ongoing
vitamin K antagonist
treatment, liver
dysfunction, pregnancy,
ongoing oral contraception
or hormonal substitution
- Free protein S
- Antigenic assay*
Deficit in
antithrombin-
III
Acute phase, liver
dysfunction, ongoing
heparin treatment,
nephrotic syndrome,
pre-eclampsia
- Antithrombin-III
activity
- Antigenic assay*
* does not detect all deficiencies.hereditary thrombophilia: i) does not increase risk of
a first VTE in such a way to outweigh the hemor-
rhagic risk of long term anticoagulation; ii) does not
increase significantly the risk of VTE recurrence; iii)
is a worst predictor for future recurrent VTE events
than clinical risk factors; iv) screening should be re-
served to subgroups of individuals for whom results
are susceptible to influence management. Moreover,
tests should be performed under optimal conditions
to avoid false positive results and consequently false
diagnosis which is potentially harmful to the patient.
Care should be taken to avoid testing in an acute
setting, to ensure patients are not on conflicting anti-
coagulants, taking concomitant oral contraception,
hormonal substitution or are pregnant.
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